OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Dr. Popat on Weighing Belantamab Mafodotin–Related Toxicities in Multiple Myeloma

Sep 27, 2021
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD
Video

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses the toxicities associated with belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, consultant hematologist, University College Hospital, honorary associate professor, University College London, discusses the toxicities associated with belantamab mafodotin-blmf (Blenrep) in relapsed/refractory multiple myeloma.

Weighing the risks and benefits of all therapies in oncology is an important step of the treatment-decision process, Popat says. Moreover, all treatment recommendations should be personalized to the individual patient.

Findings from the phase 2 DREAMM-2 trial (NCT03525678), which led to the August 2020 FDA approval of belantamab mafodotin, demonstrated clinical activity and a tolerable safety profile with the antibody-drug conjugate in patients with heavily pretreated relapsed/refractory multiple myeloma. Notably, most patients who required treatment discontinuations stopped treatment because of disease progression rather than adverse effects (AEs), Popat says.

Regardless, making a patient aware of the potential toxicities associated with belantamab mafodotin, including thrombocytopenia and keratopathy, is critical, Popat explains. Moreover, explaining how these AEs could affect a patient’s quality of life, as well as the how the efficacy of the agent compares with that of standard of care therapies, is important, Popat concludes.

Related Videos
J. Randolph (Randy) Hecht, MD
Qian (Janie) Qin, MD
Ajai Chari, MD
Joachim G. J. V. Aerts, MD, PhD
Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.
Expert on MM
Expert on MM
Naval G. Daver, MD
Pasi A. Jänne, MD, PhD
Related Content

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

September 25th 2023

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023

FDA Grants Orphan Drug Designation to NXC-201 for AL Amyloidosis

September 21st 2023

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 4th 2023

Extended Melphalan Flufenamide Indication Approaches EU Approval for R/R Multiple Myeloma

September 14th 2023

FDA Approves Motixafortide Plus Filgrastim for ASCT in Multiple Myeloma

September 11th 2023

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

September 25th 2023

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023

FDA Grants Orphan Drug Designation to NXC-201 for AL Amyloidosis

September 21st 2023

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 4th 2023

Extended Melphalan Flufenamide Indication Approaches EU Approval for R/R Multiple Myeloma

September 14th 2023

FDA Approves Motixafortide Plus Filgrastim for ASCT in Multiple Myeloma

September 11th 2023

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

September 25th 2023

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023

FDA Grants Orphan Drug Designation to NXC-201 for AL Amyloidosis

September 21st 2023

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 4th 2023

Extended Melphalan Flufenamide Indication Approaches EU Approval for R/R Multiple Myeloma

September 14th 2023

FDA Approves Motixafortide Plus Filgrastim for ASCT in Multiple Myeloma

September 11th 2023
Related Content
Advertisement
Angela Dispenzieri, MD

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

September 25th 2023
Article
Ajay K. Nooka, MD, MPH, FACP

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023
Podcast
FDA Grants Orphan Drug Designation to NXC-201 for AL Amyloidosis

FDA Grants Orphan Drug Designation to NXC-201 for AL Amyloidosis

September 21st 2023
Article
Saad Z. Usmani, MD, MBA, FACP

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 4th 2023
Podcast
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding a Type II variation application to extend the therapeutic indication of melphalan flufenamide for use in adult patients with multiple myeloma who have received at least 2 prior lines of treatment and whose disease is refractory to lenalidomide and the last line of therapy.

Extended Melphalan Flufenamide Indication Approaches EU Approval for R/R Multiple Myeloma

September 14th 2023
Article
FDA

FDA Approves Motixafortide Plus Filgrastim for ASCT in Multiple Myeloma

September 11th 2023
Article

Latest Conference Coverage

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact